Published 4 years ago • loading... • Updated 4 years ago
NCI-led clinical trial results in the first approval of a treatment for advanced alveolar soft part sarcoma
Summary by Ground News
The immunotherapy drug atezolizumab (Tecentriq) was recently approved by the U.S. Food and Drug Administration. About 80 people in the United States are diagnosed with ASPS every year. About a third of patients responded to the treatment with some degree of tumor shrinkage.